Streetwise Articles
Medical Use of Nitric Oxide Expands as Costs Come Down
Source: Streetwise Reports (9/19/18)
Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus' unique, low-cost delivery system.
More >
Coverage Initiated on 'Emerging Antibiotics Growth Story with Multiple Levers for Upside'
Source: Streetwise Reports (9/19/18)
An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm.
More >
Cancer Vaccine Developer Expands Its Collaboration with Merck
Source: Streetwise Reports (9/19/18)
A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner.
More >
U.S. Biotech Partner Obtains Marketing Authorization for ADHD Treatment in Taiwan
Source: Streetwise Reports (9/18/18)
Permission has been obtained to distribute time-release capsules.
More >
Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment
Source: Daniel Carlson for Streetwise Reports (9/14/18)
With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center.
More >
Canadian Biopharma to Outlicense Pain Drug to South Korean Firm
Source: Streetwise Reports (9/12/18)
An Echelon Wealth Partners report discussed the deal terms.
More >
Biopharma's Positive FDA Meeting Outlines Path Forward for Trial
Source: Streetwise Reports (9/11/18)
A ROTH Capital Partners note explained the outcome of the tête-a-tête and its implications.
Coverage Initiated on Firm with Paradigm-Shifting Colonoscopy Device
Source: Streetwise Reports (9/5/18)
A Ladenburg Thalmann report covered the asset, product market and financial projections of this Florida-based company.
More >
Final Approval of Biopharma's Lead Candidate Both Likely and Imminent
Source: Streetwise Reports (9/5/18)
A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication.
More >
Drug Company Receives $5 Million Milestone Payment
Source: Streetwise Reports (8/31/18)
Company entitled to receive quarterly earn-out payments from patent agreement.
More >
Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer's Treatment
Source: Streetwise Reports (8/29/18)
The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development.
More >
Oncology-Focused Biotech Receives Orphan Status for AML Drug
Source: Streetwise Reports (8/29/18)
An H.C. Wainwright & Co. report provided an update on two of this company's four product candidates.
More >
Investor Opportunity Arises from Biopharma's Share Price Weakness on Competitor News
Source: Streetwise Reports (8/29/18)
An analyst discussed the implications to this firm of a competitive product's advancement.
More >
As Nitric Oxide Comes Off Patent, Lower-Cost Options for Life Saving Drug Becoming Possible
Source: Streetwise Reports (8/22/18)
Dr. Ronald Day, a pediatric cardiologist at the University of Utah, has been using nitric oxide to treat children with pulmonary hypertension. Now, with a court ruling invalidating much of a drug patent for nitric oxide, lower-cost options might become available.
More >
Coverage Initiated on Developer of Brachytherapy Products for Cancer Treatment
Source: Streetwise Reports (8/22/18)
H.C. Wainwright & Co. analyst Jason Kolbert provided the rationale for investment in this company.
More >
Biosciences Company Announces Research Collaboration for Testing Cannabis Ingredients
Source: Streetwise Reports (8/21/18)
The development of analytic methods is a key milestone in the development of water-soluble cannabis technology.
More >
Medical Device Firm Anticipates Benefit from Patent Ruling
Source: Streetwise Reports (8/15/18)
This company, which develops delivery products for inhaled nitric oxide, a gas used to treat newborns with low oxygen levels and patients with COPD, sees opportunity in a newly invalidated patent.
More >
Medical Device Firm's Clinical Programs Progress in Q2/18
Source: Streetwise Reports (8/15/18)
A Ladenburg Thalmann report reviewed the recent financial results for a California-based company that has developed treatments for vaginal laxity and female stress urinary incontinence.
More >
Biotech Marks Progress on Programs for Cancer, Infectious Diseases
Source: Streetwise Reports (8/15/18)
This firm, focused on immuno-oncology and infectious diseases including Ebola and Zika, is moving forward on a variety of fronts, according to a Maxim Group analyst.
More >
Biopharma Signs Multimillion-Dollar Deal for Key Products in China
Source: Streetwise Reports (8/8/18)
An H.C. Wainwright & Co. report reviewed the arrangement.
More >
U.S. Medical Device Firm Pursues ISO 13485 Certification
Source: Streetwise Reports (8/1/18)
With this move, this company aims for fast-tracked regulatory approval for its nitric oxide delivery system.
More >
Cash Stream from Licensing Deal to Help Biopharma Advance Lead Drug
Source: Streetwise Reports (8/1/18)
A Laidlaw & Co. report discussed this firm's revenue and near-term, clinical catalysts.
More >
Biotech Releases White Paper on Alzheimer's Disease Candidate
Source: Streetwise Reports (8/1/18)
A company focused on treatment of neurodegenerative diseases has issued a white paper discussing its lead candidate.
More >
Interim Readout for Pharma Trial 'Delivers Home Run'
Source: Streetwise Reports (7/31/18)
An H.C. Wainwright & Co. report discussed the implications of data indicating "overwhelming evidence of efficacy" for this company's nonantibiotic anti-infective for treatment of catheter-related bloodstream infections.
More >
Health Technology Stock 'Set to Break Higher'
Source: Clive Maund for Streetwise Reports (7/24/18)
Technical analyst Clive Maund charts a health technology stock whose platform allows hospitals and healthcare organizations to buy, sell and trade surplus medical equipment and supplies.
More >
